• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine (NQ: EDIT )

    2.910 +0.010 (+0.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Editas Medicine

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
    Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
    Via Benzinga
    Exposures Product Safety
    Biotech Playbook Revisited As Technicals Weaken
    Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still... 
    Via Talk Markets
    Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
    Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
    Via Benzinga
    'Fast Money Halftime Report' Picks For September 13
    On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside... 
    Via Benzinga
    10 Biggest Price Target Changes For Friday
    Wells Fargo lowered the price target on General Motors Company (NYSE: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
    Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE: 
    Via Benzinga
    3 Red-Hot Healthcare Stocks to Buy in September
    These businesses are firing on all cylinders. 
    Via The Motley Fool
    Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
    Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
    Via InvestorPlace
    60 Biggest Movers From Yesterday
    Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,... 
    Via Benzinga
    Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
    Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
    Via InvestorPlace
    35 Stocks Moving In Monday's Mid-Day Session
    Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value... 
    Via Benzinga
    25 Stocks Moving in Monday's Pre-Market Session
    Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X... 
    Via Benzinga
    Editas Medicine Unveils Preclinical Data From New Gene Editing Technology
    Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were... 
    Via Benzinga
    Will Moderna Buy Editas Medicine to Jump Into Gene Editing?
    Editas could be an attractive acquisition candidate for the big vaccine maker. 
    Via The Motley Fool
    Why Editas Medicine Beat the Market on Monday
    Another analyst ups his recommendation on the stock. 
    Via The Motley Fool
    Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
    Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ: 
    Via Benzinga
    Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
    Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
    Via InvestorPlace
    99 Biggest Movers From Yesterday
    Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
    Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
    Via Benzinga
    10 Biggest Price Target Changes For Thursday
    Keybanc boosted the price target for HubSpot, Inc. (NYSE: 
    Via Benzinga
    Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript
    EDIT earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Editas Medicine Stock Shows Improved Relative Strength Rating
    A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue? 
    Via Investor's Business Daily
    Editas Stock Isn’t Worth Buying This Early Into Treatment Development
    EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term. 
    Via InvestorPlace
    Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
    After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
    Via The Motley Fool
    After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
    It's a good time to be a gene-editing company. 
    Via The Motley Fool
    WHO Issues Framework For Governance For Gene Editing Technologies
    A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
    Via Benzinga
    A Comprehensive Guide To Genomic ETFs
    Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
    Via Talk Markets
    Is It Too Late to Buy Intellia Therapeutics?
    After skyrocketing 68% last week, will this stock keep running higher? 
    Via The Motley Fool
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Gainers Advaxis (NASDAQ:ADXS) shares increased by 43.13% to $0.68 during Tuesday's regular session. The current volume of 106.3 million shares is 1084.49% of Advaxis... 
    Via Benzinga
    Here's What Drove Gene Editing Stocks Higher This Week
    The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers. 
    Via The Motley Fool
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.